PL3684370T3 - Kompozycja i leczenie zaniku geograficznego fludrokortyzonem - Google Patents

Kompozycja i leczenie zaniku geograficznego fludrokortyzonem

Info

Publication number
PL3684370T3
PL3684370T3 PL19756827.2T PL19756827T PL3684370T3 PL 3684370 T3 PL3684370 T3 PL 3684370T3 PL 19756827 T PL19756827 T PL 19756827T PL 3684370 T3 PL3684370 T3 PL 3684370T3
Authority
PL
Poland
Prior art keywords
fludrocortisone
treatment
composition
geographic atrophy
atrophy
Prior art date
Application number
PL19756827.2T
Other languages
English (en)
Inventor
Philip Leslie Penfold
Original Assignee
Eye Co Pty Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018900607A external-priority patent/AU2018900607A0/en
Application filed by Eye Co Pty Ltd. filed Critical Eye Co Pty Ltd.
Publication of PL3684370T3 publication Critical patent/PL3684370T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1858Platelet-derived growth factor [PDGF]
    • A61K38/1866Vascular endothelial growth factor [VEGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL19756827.2T 2018-02-26 2019-02-26 Kompozycja i leczenie zaniku geograficznego fludrokortyzonem PL3684370T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2018900607A AU2018900607A0 (en) 2018-02-26 Composition and method of treatment for geographic atrophy or dry amd
PCT/AU2019/000023 WO2019161434A1 (en) 2018-02-26 2019-02-26 Composition and method of treatment for dry a.m.d. (age related macular degeneration)

Publications (1)

Publication Number Publication Date
PL3684370T3 true PL3684370T3 (pl) 2025-07-28

Family

ID=67686647

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19756827.2T PL3684370T3 (pl) 2018-02-26 2019-02-26 Kompozycja i leczenie zaniku geograficznego fludrokortyzonem

Country Status (8)

Country Link
US (1) US20210069213A1 (pl)
EP (1) EP3684370B1 (pl)
JP (1) JP7326350B2 (pl)
CN (1) CN111886013A (pl)
AU (1) AU2019225388B2 (pl)
ES (1) ES3035108T3 (pl)
PL (1) PL3684370T3 (pl)
WO (1) WO2019161434A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025507416A (ja) * 2022-02-15 2025-03-18 アイ コ ピーティーワイ リミテッド 解剖学的及び機能的な網膜萎縮の治療
CN118490807A (zh) * 2024-05-09 2024-08-16 无锡市第二人民医院 一种补体C5a在制备治疗眼科疾病药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1755616T1 (sl) * 2004-04-08 2014-04-30 Eye Co Pty Ltd. Zdravljenje eksudativne retinopatije z mineralkortikoidi
CN106232123A (zh) * 2013-12-17 2016-12-14 眼力有限公司 玻璃体注射类固醇生物利用度的优化

Also Published As

Publication number Publication date
EP3684370A1 (en) 2020-07-29
ES3035108T3 (en) 2025-08-28
CN111886013A (zh) 2020-11-03
WO2019161434A9 (en) 2020-05-28
AU2019225388A1 (en) 2020-04-09
US20210069213A1 (en) 2021-03-11
EP3684370A4 (en) 2021-07-07
AU2019225388B2 (en) 2021-07-08
JP2021515041A (ja) 2021-06-17
WO2019161434A1 (en) 2019-08-29
JP7326350B2 (ja) 2023-08-15
EP3684370C0 (en) 2025-05-14
EP3684370B1 (en) 2025-05-14

Similar Documents

Publication Publication Date Title
GB2582482B (en) CASZ compositions and methods of use
GB2582100B (en) CAS12C Compositions and methods of use
SG11202004680UA (en) Cellular compositions and methods of treatment i
IL276135A (en) Preparations and methods of use
GB202105087D0 (en) Microbial compositions and methods of use
ZA201906169B (en) Synthekine compositions and methods of use
IL275182A (en) Preparations and methods for the treatment of metabolic conditions
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL283387A (en) Diarylhydantoin compounds and methods of use thereof
EP3606493A4 (en) DENTAL CEMENT COMPOSITIONS AND METHOD OF USE
GB2568562B (en) Moldable compositions and methods of using thereof
PL3684370T3 (pl) Kompozycja i leczenie zaniku geograficznego fludrokortyzonem
IL250852A0 (en) Periodontal preparation and method of use
GB202115731D0 (en) Compounds and methods of use
GB201810923D0 (en) Compositions and method of treatment
ZA202007107B (en) Compositions comprising pcsk9-binding molecules and methods of use
GB201919385D0 (en) Compositions and methods of manufacture
GB201919180D0 (en) New composition of matter
GB201710491D0 (en) Composition and methods of treatment
HK40065278A (en) Nanotransposon compositions and methods of use
GB201810925D0 (en) Compositions and methods of treatment
HK40049684A (en) Bismuth-thiol compositions and methods of use
ZA202004110B (en) Compositions and methods for the treatment of metabolic conditions
HK40042765B (en) Sirt1-sarna compositions and methods of use
HK40042765A (en) Sirt1-sarna compositions and methods of use